BioCentury | Nov 30, 2018
Financial News

ViaCyte attracts crossover investors for $80M series D

...ViaCyte to Develop Immune-evasive Pancreatic Cells" ). Also in September, ViaCyte raised $10 million from W.L. Gore...
BioCentury | Nov 29, 2018
Financial News

ViaCyte attracts crossover investors for $80M series D

...ViaCyte to Develop Immune-evasive Pancreatic Cells" ). Also in September, ViaCyte raised $10 million from W.L. Gore...
BioCentury | Jan 21, 2013
Company News

GI Dynamics, W.L. Gore & Associates gastrointestinal news

...up to three, six and 12 months of treatment. GI Dynamics Inc. (ASX:GID), Lexington, Mass. W.L. Gore...
BioCentury | Mar 30, 1998
Company News

Angiotech, W.L. Gore & Associates Inc. deal

...could prevent tissue overgrowth that occurs with vascular grafts. Angiotech Pharmaceuticals Inc. (TSE:ANP), Vancouver, B.C. W.L. Gore...
Items per page:
1 - 4 of 4
BioCentury | Nov 30, 2018
Financial News

ViaCyte attracts crossover investors for $80M series D

...ViaCyte to Develop Immune-evasive Pancreatic Cells" ). Also in September, ViaCyte raised $10 million from W.L. Gore...
BioCentury | Nov 29, 2018
Financial News

ViaCyte attracts crossover investors for $80M series D

...ViaCyte to Develop Immune-evasive Pancreatic Cells" ). Also in September, ViaCyte raised $10 million from W.L. Gore...
BioCentury | Jan 21, 2013
Company News

GI Dynamics, W.L. Gore & Associates gastrointestinal news

...up to three, six and 12 months of treatment. GI Dynamics Inc. (ASX:GID), Lexington, Mass. W.L. Gore...
BioCentury | Mar 30, 1998
Company News

Angiotech, W.L. Gore & Associates Inc. deal

...could prevent tissue overgrowth that occurs with vascular grafts. Angiotech Pharmaceuticals Inc. (TSE:ANP), Vancouver, B.C. W.L. Gore...
Items per page:
1 - 4 of 4